Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics announced a reverse stock split on July 25, 2025, which was effected on August 5, 2025. On July 29, 2025, it received FDA Fast Track Designation for CLD-201 for soft tissue sarcoma. The company closed a $6.9 million public offering on August 21, 2025. On October 22, 2025, it established a Scientific Advisory Board. An investor event was held on November 7, 2025, at the SITC Annual Meeting, with new data on CLD-401 unveiled on November 10, 2025, and a webinar on November 19, 2025. Third-quarter 2025 financial results were reported on November 13, 2025. The company's share price experienced a significant decline of 94.65% between November 21, 2024, and November 20, 2025, with recent declines of -6.53% and -8.33% in the past week and month, respectively, as of April 9, 2024.

The demand for Calidi Biotherapeutics' products and services does not typically exhibit seasonality. Demand is driven by clinical trial progress, regulatory approvals, and the medical need for effective cancer treatments, rather than seasonal fluctuations. The company's focus on research and development means that demand is more influenced by scientific breakthroughs, clinical trial results, and market access.

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing cancer therapies. The company uses allogeneic stem cell-based and enveloped virus platforms to deliver oncolytic viruses that target and destroy cancer cells. Its product pipeline includes CLD-101 in Phase 1b/2 trials for high-grade glioma, CLD-201 (SuperNova) in preclinical studies for solid tumors with FDA Fast Track Designation for soft tissue sarcoma, CLD-301 in preclinical studies for multiple indications, CLD-400 in preclinical studies for lung cancers and metastatic solid tumors, the NeuroNova Platform for brain cancers, the SuperNova Platform for solid tumors, and the RedTail Platform for systemic delivery of viral therapies.

Calidi Biotherapeutics is headquartered in San Diego, California, United States. The company is also working to establish a presence in Europe and Asia.

Calidi Biotherapeutics' reputation has been influenced by advancements in clinical development and strategic activities. The FDA Fast Track Designation for CLD-201 and presentation of new data on CLD-401 at SITC have positively impacted its reputation. Successful public offerings and financial reporting, including a strengthened balance sheet, have also contributed positively. The establishment of a Scientific Advisory Board has bolstered its scientific rigor. However, the significant decline in stock price has negatively impacted investor perception.

The ownership of Calidi Biotherapeutics is a mix of institutional, retail, and individual investors. As of March 31, 2025, approximately 15.43% of the stock was held by institutional investors, 3.63% by insiders, and 80.94% by public companies and individual investors. Major institutional shareholders include HighTower Advisors, LLC, Vanguard Group Inc, and Geode Capital Management, Llc. Scott Leftwich is noted as owning the most shares among individual investors.